Incyclix Bio
Durham, US · Founded 2020 · Delaware LLC · 4 known investors
Find your way into Incyclix Bio
140 people in our graph share verified history with the Incyclix Bio team — schools, employers, funds. One of them is your warm intro.
Clint Myersunlockedknows Patrick Roberts · together at The University of North Carolina at Chapel Hill (overlapped)
×11knows the team · via The University of North Carolina at Chapel Hill
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2. The company focuses on drug development for patients with advanced and resistant cancers.
Founders & leadership
PR
Patrick RobertsinChief Executive Officer and Co-FounderPatrick Roberts spent over a decade in oncology drug development, including roles in discovery and clinical advancement at G1 Therapeutics, where he contributed to the company's growth from a UNC Chapel Hill incubator stage startup through its public listing. He led translational medicine and nonclinical/clinical teams, and is an inventor on patents supporting multiple clinical-stage compounds in cell cycle targeting.
Board
FN
Fredric N. EshelmanExecutive Officer and member of the Board of Managers.
SS
Sid SubramonyMember of the Board of Managers.
NS
Norman SharplessMember of the Board of Managers.
Investors · 4
Reported raises · per SEC filings
Form D private placements$26.2M disclosed across 2 rounds · 2022–2025
▶$11.2MraisedAug 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$11.2MraisedAug 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Norman SharplessDirector
- Fredric N. EshelmanExecutive Officer, Director
- Patrick RobertsExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $11.2M
- First sale
- Aug 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$15MraisedJul 2023 · 5 investors · PharmaceuticalsRule 506(b)
▶$15MraisedJul 2023 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sid SubramonyDirector
- Patrick RobertsExecutive Officer, Director
- Fredric N. EshelmanExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $15M
- First sale
- Feb 2022
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Exelixis6 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Incyte Corporation4 shared keywordsIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Bicycle3 shared keywordsBicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.
Companies competing with Incyclix Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Incyclix Bio do?
- Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2. The company focuses on drug development for patients with advanced and resistant cancers.
- Who are Incyclix Bio's investors?
- Incyclix Bio's investors include Cape Fear BioCapital, Eshelman Ventures, LLC, Hatteras Venture Partners, Hatteras.
- How much funding has Incyclix Bio raised?
- Incyclix Bio has disclosed $26.2M raised across 2 rounds.
- Where is Incyclix Bio headquartered?
- Incyclix Bio is headquartered in Durham, US.